Hansa Biopharma (Hansa) delivers another quarter with improved Idefirix European sales. The positive Q1 surprise is almost matched in Q2, and sales seem to be above both consensus and our expectations. Hansa has also secured non-equity dilutive funding to 2024 with a secured debt arrangement with US NovaQuest Capital Management. We expect a distinct positive reaction compared with the regional equity market.